Diffuse alveolar haemorrhage in ANCA-associated vasculitis

Internal Medicine

Volumn 52, Issue 1, 2013, Pages 5-13

  West, Stephen ^a   Arulkumaran, Nishkantha ^a   Ind, Phillip W ^a   Pusey, Charles D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Alveolar haemorrhage; ANCA; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; RITUXIMAB; THYMOCYTE ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CHURG STRAUSS SYNDROME; CYTOPENIA; DIFFUSE ALVEOLAR HAEMORRHAGE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; DYSPNEA; FIBEROPTIC BRONCHOSCOPY; GRANULOMATOSIS; HEMOPTYSIS; HEMORRHAGIC CYSTITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LUNG BIOPSY; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG LAVAGE; MICROSCOPIC POLYANGIITIS; MULTICENTER STUDY (TOPIC); PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BRONCHIAL DISEASES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEMOPTYSIS; HEMORRHAGE; HUMANS; MALE; PLASMAPHERESIS; PROGNOSIS; PULMONARY ALVEOLI; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84871978814     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8863     Document Type: Review

References (72)

1. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64: 843-853, 2012.
2. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 337: 1512-1523, 1997.
3. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43: 414-419, 2000.
4. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2: 265-270, 1958.
5. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7: 23-32, 1996.
6. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41: 776-784, 2003.
7. Lee RW, D'Cruz DP. Pulmonary renal vasculitis syndromes. Autoimmun Rev 9: 657-660, 2010.
8. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994.
9. Chen M, Zhao MH. Severe pulmonary hemorrhage in patients with end-stage renal disease in antineutrophil cytoplasmic autoantibody-associated vasculitis. Am J Med Sci 337: 411-414, 2009.
10. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 39: 42-47, 2002.
11. Haworth SJ, Savage CO, Carr D, Hughes JM, Rees AJ. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. Br Med J (Clin Res Ed) 290: 1775-1778, 1985.
12. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42: 1149-1153, 2003.
13. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 79: 222-233, 2000.
14. Lin Y, Zheng W, Tian X, Zhang X, Zhang F, Dong Y. Antineutrophil cytoplasmic antibody-associated vasculitis complicated with diffuse alveolar hemorrhage: a study of 12 cases. J Clin Rheumatol 15: 341-344, 2009.
15. Ravindran V, Watts RA. Pulmonary haemorrhage in ANCA-associated vasculitis. Rheumatology (Oxford) 49: 1410-1412, 2010.
16. ter Maaten JC, Franssen CF, Gans RO, van Schijndel RJ, Hoorntje SJ. Respiratory failure in ANCA-associated vasculitis. Chest 110: 357-362, 1996.
17. Kostianovsky A, Hauser T, Pagnoux C, et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 30 Suppl 70: S77-S82, 2012.
18. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.
19. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42: 421-430, 1999.
20. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 97: 906-912, 1990.
21. Cortese G, Nicali R, Placido R, Gariazzo G, Anro P. Radiological aspects of diffuse alveolar haemorrhage. Radiol Med 113: 16-28, 2008.
22. Marasco WJ, Fishman EK, Kuhlman JE, Hruban RH. Acute pulmonary hemorrhage. CT evaluation. Clin Imaging 17: 77-80, 1993.
23. Hansell DM. Small-vessel diseases of the lung: CT-pathologic correlates. Radiology 225: 639-653, 2002.
24. Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr 28: 710-716, 2004.
25. Roccatello D, Baldovino S, Alpa M, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26 Suppl 49: S67-S71, 2008.
26. Perez-Arellano JL, Losa Garcia JE, Garcia Macias MC, Gomez Gomez F, Jimenez Lopez A, de Castro S. Hemosiderin-laden macrophages in bronchoalveolar lavage fluid. Acta Cytol 36: 26-30, 1992.
27. Linder J, Robbins R, Rennard S. Cytologic criteria for diffuse alveolar hemorrhage. Acta Cytol 32: 763, 1988.
28. Epstein CE, Elidemir O, Colasurdo GN, Fan LL. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest 120: 2013-2020, 2001.
29. Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J 14: 118-124, 1999.
30. Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. N Engl J Med 295: 1391-1396, 1976.
31. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med 75: 258, 260, 264-265, 2008.
32. Rolla G, Heffler E, Guida G, Bergia R, Bucca C. Exhaled NO in diffuse alveolar haemorrhage. Thorax 60: 614-615, 2005.
33. Gaudin PB, Askin FB, Falk RJ, Jennette JC. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and antimyeloperoxidase. Am J Clin Pathol 104: 7-16, 1995.
34. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 135: 921-930, 1989.
35. Mark EJ, Ramirez JF. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis. Arch Pathol Lab Med 109: 413-418, 1985.
36. Bosch X, Lopez-Soto A, Mirapeix E, Font J, Ingelmo M, Urbano-Marquez A. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 118: 517-522, 1994.
37. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15: 315-333, 1991.
38. Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopa-thologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 14: 1112-1125, 1990.
39. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61: 80-89, 2002.
40. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 285: 1493-1496, 1971.
41. Lockwood CM, Pinching AJ, Sweny P, et al. Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1: 63-67, 1977.
42. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology (Carlton) 14: 42-48, 2009.
43. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclo-phosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010.
44. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180-2188, 2007.
45. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134: 1033-1042, 2001.
46. Falk RJ, Jennette JC. ANCA are pathogenic--oh yes they are! J Am Soc Nephrol 13: 1977-1979, 2002.
47. Pankhurst T, Savage CO. Pathogenic role of anti-neutrophil cytoplasmic antibodies in vasculitis. Curr Opin Pharmacol 6: 190-196, 2006.
48. Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 20: 263-270, 2011.
49. Hansch GM, Andrassy K. Pathophysiology of ANCA-associated vasculitis: are ANCA really pathogenic? A note of caution. Kidney Int 66: 2090; author reply -1, 2004.
50. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclo-phosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010.
51. Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis: a multicentre randomised controlled trial - PEXIVAS 2010; Available from: http://www.bctu.bham.ac.uk/pexivas/
52. Koch M, Kohnle M, Trapp R. A case report of successful longterm relapse control by protein-a immunoadsorption in an immunosuppressive-treated patient with end-stage renal disease due to Wegener's granulomatosis. Ther Apher Dial 13: 150-156, 2009.
53. Matic G, Michelsen A, Hofmann D, et al. Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher 5: 68-72, 2001.
54. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 69: 2125-2130, 2010.
55. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433-439, 2000.
56. Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 68: 1125-1130, 2009.
57. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15: 717-721, 2004.
58. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67: 1322-1327, 2008.
59. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621-631, 2005.
60. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150: 670-680, 2009.
61. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67: 1004-1010, 2008.
62. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of anti-neutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43: 2025-2033, 2000.
63. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16: 2018-2027, 2001.
64. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients. Rheumatology (Oxford) 44: 495-501, 2005.
65. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361, 2005.
66. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44, 2003.
67. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304: 2381-2388, 2010.
68. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335: 16-20, 1996.
69. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19: 1403-1411, 2004.
70. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 265: 496-506, 2009.
71. Zhang X, Dong Y, Zeng X, Li Y, Tang F. Clinical and pathological manifestations of patients with antineutrophil cytoplasmic autoantibodies directed against proteinase 3 or myeloperoxidase. Chin Med Sci J 17: 32-35, 2002.
72. Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: A retrospective observational cohort study. Rheumatology (Oxford) 50: 2011.